abs269.txt	the	us	food	and	drug	administration	critical	path	institute'spatient-reported	outcome	(pro)	consortium	convened	a	cosponsored	workshop	on	theuse	of	pro	measures	to	inform	assessment	safety	tolerability	in	cancerclinical	trials		broad	array	international	stakeholders	involved	oncologydrug	development	measurement	science	provided	perspectives	role	ofpro	provide	complementary	clinical	data	symptomatic	sideeffects	anticancer	agents	speakers	panelists	explored	utility	ofinformation	derived	from	existing	emerging	focusing	proversion	national	cancer	institute's	common	terminology	criteria	foradverse	events	discussed	potential	ways	improve	thecollection	analysis	presentation	describing	adverseevents	support	better	regulatory	treatmentdecisions	participants	concluded	day	with	discussion	possibleapproaches	patient-reported	an	investigational	drug'soverall	side	effect	burden	as	trial	end	point	anddrug	reiterated	its	commitment	collaborate	internationaldrug	identify	rigorous	methods	incorporate	thepatient	perspective	into	therapeutics
